REG - ConvaTec Group PLC - Director Declaration

ConvaTecAnnouncement

07/07/2022 12:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220707:nRSG6985Ra&default-theme=true

RNS Number : 6985R  ConvaTec Group PLC  07 July 2022

Convatec Director Declaration

Reading, United Kingdom (7 July 2022)

 

Convatec Group Plc ("Convatec" or "the Company") announces that Sharon
O'Keefe, a non-executive director of the Company, has been appointed as a
non-executive director of Apollo Endosurgery Inc. (Nasdaq: APEN), with effect
from 6 July 2022.

 

This announcement is made in accordance with Listing Rule 9.6.14R.

 

 

Enquiries

Analysts and Investors

Kate Postans, VP Investor Relations,
Convatec
+44 (0)782 644 7807

ir@convatec.com (mailto:ir@convatec.com)

 

Media

Buchanan: Charles Ryland / Chris Lane                
 
+44 (0)207 466 5000                 
                        

Convatec Group Plc's LEI code is 213800LS272L4FIDOH92

 

About Convatec

Pioneering trusted medical solutions to improve the lives we touch: Convatec
is a FTSE 250 global medical products and technologies company, focused on
solutions for the management of chronic conditions, with leading positions in
advanced wound care, ostomy care, continence and critical care, and infusion
care. Group revenues in 2021 were over $2 billion. With around 10,000
colleagues, we provide our products and services in over 100 countries, united
by a promise to be forever caring. Our products provide a range of benefits,
from infection prevention and protection of at-risk skin, to improved patient
outcomes and reduced care costs. To learn more about Convatec, please visit
http://www.convatecgroup.com (http://www.convatecgroup.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RDNUPUGAMUPPGUM